Tag: Immunotherapy
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival
FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma
Significantly improved progression-free survival seen with Monjuvi in combination with rituximab and lenalidomide
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ T-cell repertoire
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer
Longer mean duration of quality-adjusted time without symptoms of disease progression or toxicity of treatment seen with dostarlimab
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
Better event-free survival outcomes seen for durvalumab plus FLOT versus FLOT alone in phase 3 randomized trial
FDA Approves Zynyz as First-Line Treatment for Advanced Anal Cancer
The programmed death receptor-1-blocking antibody is approved as a single agent or in combination with chemotherapy
Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
Real-world benefit seen with addition of bevacizumab to first-line chemotherapy for patients with high‐risk prognostic factors
Peanut Oral Immunotherapy Efficacious in Allergic Adults
Median tolerated dose increased from 30 mg to 3,000 mg of peanut protein at the exit challenge, equivalent to 12 peanuts
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
Neoadjuvant PD-1 blockade with dostarlimab enables nonoperative management strategy for large proportion of patients
